The revised manuscript by Shukla et al. provides important mechanistic insights into kinesin-1 autoinhibition and cargo-mediated activation. Through a convincing integration of protein engineering, ...

Star map showing the position of NEO Asteroid 2026 CC3 in the constellation of Hydra Asteroid 2026 CC3 will be flying by Earth very closely today. The newly spotted celestial object is approximately ...

Asteroid 2026 CC3 will pass Earth safely on March 11, 2026. The asteroid is about 33 feet wide, similar to a city bus. Scientists confirm no impact risk from 2026 CC3 during its flyby. Did our AI ...

StarHub is one of Singapore’s leading telecommunications and media companies, best known for providing mobile, broadband, pay-TV, and enterprise solutions to both consumers and businesses. It is a ...

Store-operated calcium entry (SOCE) is essential for many physiological processes, and inadequate regulation of this pathway leads to a variety of human diseases. The ER calcium-sensing protein STIM1 ...

After a brief run back in April, Humble Bundle's Map Making Mega Bundle just got an encore that lasts until Dec. 2 at 2 p.m. EST. Described as a "treasure trove of assets and apps" released by ...

The Creator Clash brand has officially been shuttered after the third influencer-boxing event was postponed from June to October 2025 amid drama between organizer iDubbbz and H3H3’s Ethan Klein.

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Picking your class is the most important choice you’ll have to make at the start of your Muffin journey. It’ll shape your gameplay, Melomon choices, and so much more. To help you make that choice and ...

We report the cryoelectron microscopy structure of the chemokine receptor XCR1 with Gi protein and XCL1. As the only known G protein-coupled receptor for XCL1, XCR1 is a marker for conventional type 1 ...

An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC).